RecruitingProstate CancerProstatic Neoplasms
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Eligible age
18+ yrs
Accepts
Men
Locations
20 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
You may qualify if…
- ✓ At least 18 years of age.
- ✓ Signed informed consent.
- ✓ Untreated, histologically confirmed adenocarcinoma of the prostate.
- ✓ High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA \>20 ng/mL).
- ✓ Patients electing to undergo RP with PLND.
You may not qualify if…
- ✕ Administration of any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
- ✕ Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
- ✕ Patients with known predominant small cell or neuroendocrine PC.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06056830 · last updated 2026-09-11